HENDERSON, NV, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioLife Sciences Inc. (“BioLife” or the “Company”) (OTCPK: BLFE)…
LEXINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection…
– Two Academic Powerhouses form Institut Pasteur-UCSF QBI Center of Excellence in Emerging Diseases with Planned Operations/Locations in San Francisco…
Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in…
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole…
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address…
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying,…
Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung DiseaseMENLO PARK, Calif., Oct. 19, 2022…
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing…
Studies demonstrate that T2Bacteria and T2Candida panels enable sensitive and specific diagnosis to enhance the standard of careLEXINGTON, Mass., Oct.…